Table 1: Antimicrobial use for all patients and by advance directive group

Among all patients	All patients (n = 1796)	POLST completed ≥ 30 days prior to death (n = 177)[a]			No POLST completed ≥ 30 days prior to death (n = 1619)
		Limited antimicrobial use (n = 58)	Full antimicrobial use (n = 79)	No antimicrobial selection (n = 40)	
Any inpatient or outpatient antimicrobial use, n (%)	1166 (65)	26 (45)	45 (57)	27 (65)	1068 (66)
Any use of anti-MRSA antibiotics[b]	716 (40)	10 (17)	32 (41)	17 (43)	657 (41)
Any use of non-fluoroquinolone antipseudomonal antibiotics[c]	808 (45)	12 (21)	36 (46)	18 (45)	742 (46)
Any use of a carbapenem antibiotic	242 (14)	3 (5)	8 (10)	5 (13)	226 (14)
Any use of a fluoroquinolone	517 (29)	11 (19)	20 (25)	13 (33)	473 (29)
Among patients with at least 1 inpatient day	All (n = 1295)	Limited (n = 34)	Full (n = 55)	No selection (n = 30)	No POLST (n = 1176)
Any inpatient antimicrobial use	1070 (83)	20 (59)	43 (78)	24 (80)	983 (84)
Inpatient antimicrobial days of therapy DOT/1000 inpatient-days, median (range)	1076.9 (0 – 7166.7)	271.4 (0 - 4933.3)	1000 (0 - 5600)	979.2 (0 - 4666.7)	1111.1 (0 - 7166.7)
Any inpatient IV antimicrobial use	996 (77)	16 (47)	42 (76)	22 (73)	916 (78)
Inpatient IV antimicrobial days of therapy DOT/1000 inpatient-days, median (range)	666.7 (0 – 4379.3)	0 (0 - 2750)	645.2 (0 - 4333.3)	556.5 (0 - 2322.6)	666.7 (0 - 4379.3)

[a] Full antibiotic use refers to the selection "Use antibiotics for prolongation of life." Limited antibiotic use refers to the selection "Do not use antibiotics except when needed for symptom management."
[b] Anti-MRSA antibiotics are vancomycin (excluding enteral administration), daptomycin, ceftaroline, and linezolid
[c] Non-fluoroquinolone antipseudomonal antibiotics are aztreonam, piperacillin, ticarcillin, ceftazidime, cefepime, ceftolozane, imipenem, meropenem, colistin, tigecycline, amikacin, gentamicin, tobramycin, and derivatives/combinations of these agents

Figure 2. Forest plot of model estimates, represented as incidence rate ratios (IRR) with 95% confidence intervals (CI), for associations between POLST antimicrobial specifications completed at least 30 days before death and inpatient antibiotic days of therapy (DOT) in the 30 days before death. Estimates represent comparisons between each POLST category and no POLST completed at least 30 days before death. Dots represent the IRR and brackets extend to the lower and upper limit of the 95% CI. Blue estimates are for the inpatient antibiotic DOT outcome and red estimates are for the inpatient IV antibiotic DOT outcome.

Conclusion: POLST completion is rare > /= 30 days before death, with few POLSTs specifying antimicrobial use. Compared to those with no POLST in this time frame, patients who indicated that antibiotics should be used only for symptom management received significantly fewer inpatient IV antimicrobials. Early discussion of advance directives including POLST with specification of antimicrobial use preferences may promote more thoughtful use of antimicrobials near the end of life in a compassionate, patient-centered way.

140. Symptoms and Situations Predispose Patients to Use Antibiotics Without Medical Advice

Michael Hansen, MD, MPH, MS[1]; Barbara Trautner, MD, PhD[2]; Roger Zoorob, MPH, MD[1]; George Germanos, MPH, MD[1]; Osvaldo Alquicira, BS[1]; juanita Salinas, BS[1]; Kenneth Barning, MB, ChB[1]; Hammad Mahmood, MBBS[1]; Malissa A. Gonzalez, DNP, RN, NEA-BC[3]; Michele Fowler, DO, MBA, FACOEP[3]; Larissa Grigoryan, MD,

PhD[1]; [1]Baylor College of Medicine, Houston, Texas; [2]Michael E DeBakey VA Medical Center, Houston, Texas; [3]Memorial Hermann, Houston, Texas

Session: O-27. Innovation in Antimicrobial Stewardship

Background: Use of antibiotics without a prescription (non-prescription use) contributes to antimicrobial resistance. Non-prescription use includes obtaining and taking antibiotics without a prescription, taking another person's antibiotics, or taking one's own stored antibiotics. We conducted a quantitative survey focusing on the factors that impact patients' decisions to use non-prescription antibiotics.

Methods: We surveyed patients visiting public safety net primary care clinics and private emergency departments in a racially/ethnically diverse urban area. Surveys were read aloud to patients in Spanish and English. Survey domains included patients' perspectives on which syndromes require antibiotic treatment, their perceptions of health care, and their access to antibiotics without a prescription.

Results: We interviewed 190 patients, 122 from emergency departments (64%), and 68 from primary care clinics (36%). Overall, 44% reported non-prescription antibiotic use within the past 12 months. Non-prescription use was higher among primary care clinic patients (63%) than the emergency department patients (39%, p = 0.002). The majority felt that antibiotics would be needed for bronchitis (78%) while few felt antibiotics would be needed for diarrhea (30%) (Figure 1).

The most common situation identified "in which respondents would consider taking antibiotics without contacting a healthcare provider was "got better by taking this antibiotic before" (Figure 2). Primary care patients were more likely to obtain antibiotics without prescription from another country than emergency department patients (27% vs. 13%, P=0.03). Also, primary care patients were more likely to report obstacles to seeking a doctor's care, such as the inability to take time off from work or transportation difficulties, but these comparisons were not statistically significant.

Figure 1. Patients' agreement that antibiotics would be needed varied by symptom/ syndrome.


Figure 2. Situations that lead to non-prescription antibiotic use impacted the two clinical populations differently

Conclusion: Non-prescription antibiotic use is a widespread problem in the two very different healthcare systems we included in this study, although factors underlying this practice differ by patient population. Better understanding of the factors driving non-prescription antibiotic use is essential to designing patient-focused interventions to decrease this unsafe practice.

141. Rapid Reduction in Concomitant Vancomycin and Piperacillin-tazobactam Use: A Model for Future Antimicrobial Stewardship Interventions

Joanna Kimball, MD[1]; Connor Deri, PharmD[2]; Nesbitt J. Nesbitt, PharmD[1];

George Nelson, MD[1]; Milner Staub, MD[3]; [1]Vanderbilt University Medical Center, Westwood, Kansas; [2]Duke University Hospital, Durham, North Carolina; [3]VHA Tennessee Valley Healthcare System, Geriatric Research Education and Clinical Center and Vanderbilt University Medical Center, Nashville, Tennessee

Session: O-27. Innovation in Antimicrobial Stewardship

Background: Concomitant vancomycin and piperacillin-tazobactam use (CVPTU) for >2 days is associated with increased nephrotoxicity. At Vanderbilt University Medical Center, a sustained decline in CVPTU was achieved. A retrospective review of CVPTU and antimicrobial stewardship (AS) interventions was performed to develop a model for future AS quality improvement (QI) initiatives.

Methods: Data for adults receiving CVPTU January 2015 - August 2019 were extracted. No patients were excluded. Change in monthly incidence of CVPTU >2 days in relation to AS interventions was the primary outcome. CVPTU was analyzed with statistical process control (SPC) charts (QI Macros 2019). AS interventions were amassed from AS emails, meeting minutes, presentations and patient-specific interventions. We created a new intervention evaluation tool using the Hierarchy of Effectiveness (1-Education, 2-Policy, 3-Reminders, 4-Simplification, 5-Automation, 6-Forced Function) and a self-designed scale of impact (1-divisional subgroup, 2-division, 3-department, 4-center-wide). Scores were summed for each 6-month period and rated as low, moderate or high intervention strength. Periods were mapped against their corresponding CVPTU rate (Figure 1).

Results: *CVPTU Data*: During periods 1–5 (January 2015 - February 2018), an average 4% of admitted patients received >2 days CVPTU, decreasing to < 1% from period 5 (March 2018) onward (Figure 1). From period 1–5, an average 52.8% of patients with CVPTU received >2 days and dropped to 41.3% from period 5 onward (Figure 2).

Intervention Data: There was 1 low, 3 moderate and 4 high intensity periods. Intensity decreased as initiatives transitioned from behavior change to sustained behavior (Figure 1). The main interventions were education and patient-specific feedback. Division-specific antibiotic algorithms and computerized order sets re-enforced behavior. Infectious diseases consults and team pharmacists embedded the concept in daily practice.

Figure 1: Proportion of All Admissions with Concomitant Vancomycin and Piperacillin-Tazobactam Use (CVPTU) for >2 Days Mapped Against Simultaneous Quality Improvement Interventions.


Figure 2: Proportion of Patients with Concomitant Vancomycin and Piperacillin-Tazobactam Use (CVPTU) for >2 Days.

Conclusion: Persistent, repetitive center-wide intervention is key to driving and sustaining change. More analysis of specific intervention types and impact of external factors would enhance understanding and future use of this AS change implementation model.

Disclosures: **All Authors**: No reported disclosures

---

142. Frequency of Short-course Empiric Antibiotic Use as an Antimicrobial Stewardship Metric

Jessina C. McGregor, PhD, FSHEA[1]; Caitlin M. McCracken, MA[2]; Samuel F. Hohmann, PhD[3]; Amy L. Pakyz, PharmD, MS, PhD[4]; [1]Oregon State University, Portland, Oregon; [2]Oregon State University College of Pharmacy, Portland, Oregon; [3]Vizient, Chicago, Illinois; [4]Virginia Commonwealth University School of Pharmacy, Richmond, Virginia

Session: O-27. Innovation in Antimicrobial Stewardship

Background: Antimicrobial stewardship metrics that provide actionable guidance are needed to support efforts to improve hospital use of antibiotics. Antibiotics such as vancomycin and piperacillin/tazobactam are common empiric agents used frequently when the infectious process remains unknown. Thus short, incomplete courses of therapy are used more frequently for such agents. We aimed to evaluate the variability in short courses of vancomycin and piperacillin/tazobactam use across U.S. hospitals.

Methods: We performed a cross-sectional study among U.S. hospitals that contributed inpatient pharmacy data to the Vizient clinical database in 2016. We identified vancomycin and piperacillin-tazobactam courses initiated within the 48 hours of admission, measured as days of therapy received. We calculated the percent of patients that received 1, 2, 3, 4 or >4 days of therapy at each facility to describe short course empiric antibiotic use. To describe the variability across facilities, we then assessed the median, interquartile range (IQR), and total range of that percentage.

Results: We identified 145 hospitals representing approximately 3.7 million patient encounters for inclusion in this study. Within 48 hours of admission, 13.9% of encounters received vancomycin, 7.7% piperacillin/tazobactam, and 4.6% received both. The figure demonstrates the variability in the frequency of short course antibiotic use across hospitals; boxes indicate the IQR with the transecting line representing the median and whiskers representing the full range. The proportion of patients that received one day of therapy varied most across hospitals, with vancomycin ranging from 0–100%. In contrast, the frequency of patients that received greater than four days of therapy varied considerably less across hospitals; 0–33% for vancomycin.

Conclusion: The variability in use of short course empiric therapies suggests that use for non-infectious processes or infections not appropriately treated by these agents varies greatly across facilities. Measuring short course use for common empiric agents may serve as an important antimicrobial stewardship metric. Such a metric could inform antimicrobial stewardship efforts to reduce unnecessary initiation of empiric antimicrobial therapy.

Disclosures: **All Authors**: No reported disclosures

---

143. Modification of Linezolid Restriction Criteria Reduces ICU Gram-positive Antibiotic Consumption

John M. Boulos, PharmD[1]; Kathryn DeSear, PharmD, BCIDP[1]; Bethany Shoulders, PharmD, BCCCP[2]; Veena Venugopalan, Doctor of Pharmacy[2]; Stacy A. Voils, PharmD, MSc[2]; Catherine Vu, PharmD[1]; Megan Logan, PharmD, BCCCP[1]; Barbara A. Santevecchi, PharmD, BCPS, BCIDP[1]; [1]University of Florida Health Shands Hospital, Durham, North Carolina [2]University of Florida College of Pharmacy, Gainesville, Florida

Session: O-27. Innovation in Antimicrobial Stewardship

Background: Antibiotic time out (ATO) policies have been proposed by the Centers for Disease Control and Prevention to limit unnecessary use of antibiotics. Critically ill patients are often treated empirically with MRSA-active agents for a prolonged duration. The objective of this study was to assess the impact of an ATO policy by targeting empiric gram-positive coverage.

Methods: Before this intervention, linezolid required pre-approval by the antimicrobial stewardship program or infectious diseases (ID) consult service before dispensing, and no automatic ATO policy was in place for any agent. In 2018, restriction of linezolid was modified to allow 72 hours of empiric use in the intensive care unit